TITLE

Safety and efficacy of estrogen therapy in preventing bone loss in primary biliary cirrhosis

AUTHOR(S)
Menon, K.V.Narayanan; Angulo, Paul; Boe, Gwen M.; Lindor, Keith D.
PUB. DATE
April 2003
SOURCE
American Journal of Gastroenterology;Apr2003, Vol. 98 Issue 4, p889
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
: ObjectivesEstrogen therapy has been found to be useful in the treatment of postmenopausal osteoporosis. However, concern about its potential for worsening cholestasis has limited its use in postmenopausal women with primary biliary cirrhosis. The aim of the present study was to determine the safety as well as the efficacy of estrogen replacement therapy with respect to bone mass in postmenopausal women with primary biliary cirrhosis.: MethodsBone mineral density of the lumbar spine (measured using dual energy x-ray absorptiometry) of 46 unselected postmenopausal women with primary biliary cirrhosis receiving estrogen replacement therapy was compared with 46 age-matched women with primary biliary cirrhosis not receiving estrogen replacement therapy, and with the expected normal bone mineral density adjusted for age and ethnic group.: ResultsThe mean duration of follow-up was 4.8 ± 0.4 yr. Treatment with estrogens resulted in a significantly lower rate of bone loss (0.002 g/cm2/yr ± 0.028 vs 0.009 g/cm2/yr ± 0.020, p = 0.05). Worsening cholestasis attributable to estrogen replacement therapy did not occur in any patient. One patient (2%) discontinued therapy because of side effects.: ConclusionsEstrogen replacement therapy in postmenopausal patients with primary biliary cirrhosis is safe and may be effective in decreasing the rate of bone loss.
ACCESSION #
9658109

 

Related Articles

  • Bone Loss after Stopping Estrogen or Alendronate Therapy.  // Annals of Internal Medicine;12/3/2002, Vol. 137 Issue 11, pI31 

    Presents a summary of an article on bone loss after estrogen or alendronate therapy published in the December 3, 2002, issue of 'Annals of Internal Medicine.' Information on osteoporosis; Focus on the rate of bone loss after stopping Premarin, alendronate and combination therapy with both drugs...

  • Intensive healing for brittle bones. Bonnick, Sydney Lou // Prevention;Jun94, Vol. 46 Issue 6, p92 

    Comments on an alternative to estrogen replacement therapy for decreasing the chances of osteoporosis in post-menopausal women. Discussion of salmon calcitonin, one of two medications currently approved by the Food and Drug Administration for the treatment of osteoporosis; Disadvantages of...

  • Significant Differential Effects of Alendronate, Estrogen, or Combination Therapy on the Rate of Bone Loss after Discontinuation of Treatment of Postmenopausal Osteoporosis. Greenspan, Susan L.; Emkey, Ronald D.; Bone III, Henry G.; Weiss, Stuart R.; Bell, Norman H.; Downs, Robert W.; McKeever, Clark; Miller, Sam S.; Davidson, Michael; Bolognese, Michael A.; Mulloy, Anthony L.; Heyden, Norman; Mei Wu; Kaur, Amarjot // Annals of Internal Medicine;12/3/2002, Vol. 137 Issue 11, p875 

    Determines the rate of bone loss when therapy with alendronate, estrogen or both agents is discontinued. Result of bone mineral density and boimechanical markers of bone turnover; Conclusion that accelerated bone loss is seen after withdrawal of estrogen therapy but not after withdrawal of...

  • Phyto-oestrogen excretion and rate of bone loss in postmenopausal women. Kardinaal, A. F. M.; Morton, M. S. // European Journal of Clinical Nutrition;Nov1998, Vol. 52 Issue 11, p850 

    Provides information on a study which tested whether the rate of postmenopausal bone loss is inversely associated with long-term urinary excretion of phyto-oestrogens. Theoretical background; Methodology; Results and discussion.

  • Raloxifene. Balfour, J.A.; Goa, K.L. // Drugs & Aging;1998, Vol. 12 Issue 4, p335 

    â–´ Raloxifene is a selective estrogen receptor modulator which mimics the effects of estrogens on bone and blood lipid levels without stimulatory effects on the breast or uterus. â–´ Raloxifene inhibits estrogen-dependent proliferation of human breast cancer cells in vitro and...

  • Estrogen deficiency and low-calcium diet increased bone loss and urinary calcium excretion but did not alter arterial stiffness in young female rats. Jong-Hoon Park; Naomi Omi; Toshiya Nosaka; Ayako Kitajima // Journal of Bone & Mineral Metabolism;May2008, Vol. 26 Issue 3, p218 

    Abstract  Many epidemiological studies have reported that the severity of arterial diseases such as arterial calcification and stiffness is inversely related to bone loss, i.e., osteoporosis. However, the nature of this relationship is unclear. The purpose of the present study was to...

  • Can Transdermal Estrogen Prevent Bone Loss? Walling, Anne D. // American Family Physician;2/1/2000, Vol. 61 Issue 3, p838 

    Discusses research on the use of transdermal estrogen in the prevention of bone loss. Reference to a study by S. R. Weiss, et al., from the September 1999 issue of the `Obstetrics & Gynecology'; Decrease in bone mass of postmenopausal women; Results of the study.

  • Low-dose estrogen may be HRT treatment option.  // Geriatrics;Dec98, Vol. 53 Issue 12, p16 

    Announces that low levels of estrogen may confer protection against osteoporosis, according to a study of postmenopausal women. Target for estrogen replacement therapy; Comment from Doctor Douglas Bauer; Background of the study.

  • Focus on alendronate. Chow, Moses S.S.; Ashworth, Laura // Formulary;Jan1996, Vol. 31 Issue 1, p23 

    Presents information on alendronate, an aminobisphosphonate compound approved for the treatment of osteoporosis in postmenopausal women. Adverse effects of alendronate; Why some patients refuse to take estrogen. INSET: Formulary considerations..

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics